CA2347081A1 - Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate - Google Patents

Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate Download PDF

Info

Publication number
CA2347081A1
CA2347081A1 CA002347081A CA2347081A CA2347081A1 CA 2347081 A1 CA2347081 A1 CA 2347081A1 CA 002347081 A CA002347081 A CA 002347081A CA 2347081 A CA2347081 A CA 2347081A CA 2347081 A1 CA2347081 A1 CA 2347081A1
Authority
CA
Canada
Prior art keywords
csg
prostate
levels
cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002347081A
Other languages
English (en)
Inventor
Susana Salceda
Herve Recipon
Robert Cafferkey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2347081A1 publication Critical patent/CA2347081A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouvelles méthodes permettant de détecter, de diagnostiquer, de surveiller, de classer par stades, de pronostiquer, de visualiser, et de traiter le cancer de la prostate.
CA002347081A 1998-10-19 1999-10-19 Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate Abandoned CA2347081A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10473798P 1998-10-19 1998-10-19
US60/104,737 1998-10-19
PCT/US1999/024331 WO2000023111A1 (fr) 1998-10-19 1999-10-19 Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate

Publications (1)

Publication Number Publication Date
CA2347081A1 true CA2347081A1 (fr) 2000-04-27

Family

ID=22302100

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002347081A Abandoned CA2347081A1 (fr) 1998-10-19 1999-10-19 Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate

Country Status (4)

Country Link
EP (1) EP1131095A4 (fr)
JP (1) JP2002527758A (fr)
CA (1) CA2347081A1 (fr)
WO (1) WO2000023111A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
ES2323407T3 (es) * 2000-07-12 2009-07-15 Agensys, Inc. Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
WO2002074907A2 (fr) * 2001-02-02 2002-09-26 Bayer Pharmaceuticals Corporation Procedes permettant de moduler la production de surfactant
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US7893197B2 (en) 2004-08-25 2011-02-22 Janssen Pharmaceutica N.V. Relaxin-3 chimeric polypeptides and their preparation and use
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US20100086912A1 (en) * 2005-11-15 2010-04-08 Clerc Roger G AZGP Gene Single Nucleotide Polymorphisms (SNPs)
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5800817B2 (ja) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CN117233413A (zh) 2019-08-05 2023-12-15 禧尔公司 用于样品制备、数据生成和蛋白质冠分析的系统和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082341B1 (fr) * 1998-06-01 2010-12-08 Agensys, Inc. Nouvel antigene tumoral utile dans le diagnostic et la therapie propres au cancer de la prostate et du colon
AU4823599A (en) * 1998-06-22 2000-01-10 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes

Also Published As

Publication number Publication date
EP1131095A1 (fr) 2001-09-12
EP1131095A4 (fr) 2003-04-23
WO2000023111A1 (fr) 2000-04-27
JP2002527758A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
CA2347081A1 (fr) Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate
Bos et al. A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene
US7432064B2 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
ES2374954T3 (es) Variaciones genéticas asociadas con tumores.
Raza-Egilmez et al. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia
US5272057A (en) Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
Smith et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction
US6017704A (en) Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
CA2442820A1 (fr) Etablissement de profils d'expression genique dans un microreseau dans un adenocarcinome a cellules claires, pronostic et identification de cible medicamenteuse
EP0854923A2 (fr) Molecules isolees d'acides nucleiques utiles comme marqueurs de la leucemie et pour pronostiquer un cancer du sein
US5945522A (en) Prostate cancer gene
Slebos et al. The ras Gene Family in Human Non-Small-Cell Lung Cancer¹
WO1993025713A9 (fr) Compositions et procedes de detection de rearrangements et de translocations de genes
Corvi et al. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells
CA2666057C (fr) Variations genetiques associees a des tumeurs
CA2219221A1 (fr) Procedes de diagnostic et therapie genique faisant appel a des reactifs derives du gene suppresseur de metastases humain kai1
Corvi et al. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line
Huber Therapeutic opportunities involving cellular oncogenes: novel approaches fostered by biotechnology
Prosperi et al. Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line
US20040106109A1 (en) Detection of ras mutations
US6255049B1 (en) Detection of metastatic cancer cells using PCTA-1
Jun et al. Establishment of immuno-PCR technique for the detection of tumor associated antigen MG 7-Ag on the gastric cancer cell line
Hong et al. A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61
US20040142328A1 (en) Method and cloning vector for preparing multiple-gene diagnostic probes for the assessment of multiple markers for breast cancer prognosis
CN115851959B (zh) 一种用于食管鳞状细胞癌及癌前病变的诊断或辅助诊断的试剂及检测试剂盒

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead